Rich66
06-01-2009, 03:35 PM
Ariad Begins Clinical Trial of Breast Cancer Drug
Luke Timmerman (http://www.xconomy.com/author/ltimmerman/) 7/30/08
Ariad Pharmaceuticals (NASDAQ: ARIA (http://finance.yahoo.com/q?s=ARIA)), the Cambridge, MA-based developer of cancer drugs, said today (http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1181159&highlight=) it has started a mid-stage clinical trial of a breast cancer treatment designed to help patients who resist Genentech’s Herceptin. The drug, an oral pill called deforolimus, is designed to block the mTOR protein, which acts like a “master switch” for cancer cells. Ariad will now receive a $15 million milestone payment from its partner, drug giant Merck (NYSE: MRK (http://finance.yahoo.com/q?s=MRK)) for starting the study. The trial, of 33 patients, should wrap up in the second half of 2009.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com or call 206-624-2374.
Comments (http://www.xconomy.com/boston/2008/07/30/ariad-pharmaceuticals-starts-clinical-trial-of-breast-cancer-drug/#comments) | Permalink (http://www.xconomy.com/boston/2008/07/30/ariad-pharmaceuticals-starts-clinical-trial-of-breast-cancer-drug/) | http://www.xconomy.com/wordpress/wp-content/themes/xconomy/images/share-icon-12x12.gif Share (http://www.xconomy.com/?p=3629&akst_action=share-this) | http://www.xconomy.com/wordpress/wp-content/plugins/wp-email/images/email_famfamfam.gif (http://www.xconomy.com/boston/2008/07/30/ariad-pharmaceuticals-starts-clinical-trial-of-breast-cancer-drug/email/) E-mail (http://www.xconomy.com/boston/2008/07/30/ariad-pharmaceuticals-starts-clinical-trial-of-breast-cancer-drug/email/)
Luke Timmerman (http://www.xconomy.com/author/ltimmerman/) 7/30/08
Ariad Pharmaceuticals (NASDAQ: ARIA (http://finance.yahoo.com/q?s=ARIA)), the Cambridge, MA-based developer of cancer drugs, said today (http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1181159&highlight=) it has started a mid-stage clinical trial of a breast cancer treatment designed to help patients who resist Genentech’s Herceptin. The drug, an oral pill called deforolimus, is designed to block the mTOR protein, which acts like a “master switch” for cancer cells. Ariad will now receive a $15 million milestone payment from its partner, drug giant Merck (NYSE: MRK (http://finance.yahoo.com/q?s=MRK)) for starting the study. The trial, of 33 patients, should wrap up in the second half of 2009.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com or call 206-624-2374.
Comments (http://www.xconomy.com/boston/2008/07/30/ariad-pharmaceuticals-starts-clinical-trial-of-breast-cancer-drug/#comments) | Permalink (http://www.xconomy.com/boston/2008/07/30/ariad-pharmaceuticals-starts-clinical-trial-of-breast-cancer-drug/) | http://www.xconomy.com/wordpress/wp-content/themes/xconomy/images/share-icon-12x12.gif Share (http://www.xconomy.com/?p=3629&akst_action=share-this) | http://www.xconomy.com/wordpress/wp-content/plugins/wp-email/images/email_famfamfam.gif (http://www.xconomy.com/boston/2008/07/30/ariad-pharmaceuticals-starts-clinical-trial-of-breast-cancer-drug/email/) E-mail (http://www.xconomy.com/boston/2008/07/30/ariad-pharmaceuticals-starts-clinical-trial-of-breast-cancer-drug/email/)